Show simple item record

dc.contributor.authorKost, Rhonda G.
dc.contributor.authorPoppel, Stephen M.
dc.contributor.authorColler, Barry S.
dc.date2022-08-11T08:11:02.000
dc.date.accessioned2022-08-23T17:29:47Z
dc.date.available2022-08-23T17:29:47Z
dc.date.issued2017-04-01
dc.date.submitted2020-05-14
dc.identifier.citation<p>Kost RG, Poppel SM, Coller BS. Informed consent for next-generation nucleotide sequencing studies: Aiding communication between participants and investigators. Version 2. J Clin Transl Sci. 2017 Apr;1(2):115-120. doi: 10.1017/cts.2016.21. Epub 2017 Feb 7. PMID: 28649453; PMCID: PMC5471895. <a href="https://doi.org/10.1017/cts.2016.21">Link to article on publisher's site</a></p>
dc.identifier.issn2059-8661 (Linking)
dc.identifier.doi10.1017/cts.2016.21
dc.identifier.pmid28649453
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50397
dc.description<p>The authors acknowledge the work of the New England Research Subject Advocacy Group, which was conducted with support from the UMass Center for Clinical and Translational Science and other centers that are part of the the National Center for Advancing Translational Sciences, National Institutes of Health.</p>
dc.description.abstractINTRODUCTION: Obtaining informed consent from prospective participants for research studies that include next-generation nucleotide sequencing (NGS) presents significant challenges because of the need to explain all the potential implications of participating, including the possible return of "incidental" findings, in easy-to-understand language. METHODS AND RESULTS: After reviewing the consent processes at other institutions, we decided to supplement the protocol-specific informed consent form with the following: (1) a short pamphlet for the prospective participant that includes a series of questions that she or he is encouraged to ask the investigator, and (2) a more detailed companion guide for investigators to help them develop simple-language answers to the questions. Both documents are available to use or modify. CONCLUSIONS: We propose an approach to obtaining informed consent for NGS studies that encourages discussion of key issues without creating a complex, comprehensive document for participants; it also maximizes investigator flexibility. We also suggest mechanisms to return restricted information to participants.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28649453&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471895/
dc.subjectUMCCTS funding
dc.subjectTranslational research
dc.subjectdesign and analysis
dc.subjectgenetic counseling
dc.subjectpatient-centered research
dc.subjectTranslational Medical Research
dc.titleInformed consent for next-generation nucleotide sequencing studies: Aiding communication between participants and investigators
dc.typeJournal Article
dc.source.journaltitleJournal of clinical and translational science
dc.source.volume1
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/umccts_pubs/222
dc.identifier.contextkey17740872
html.description.abstract<p>INTRODUCTION: Obtaining informed consent from prospective participants for research studies that include next-generation nucleotide sequencing (NGS) presents significant challenges because of the need to explain all the potential implications of participating, including the possible return of "incidental" findings, in easy-to-understand language.</p> <p>METHODS AND RESULTS: After reviewing the consent processes at other institutions, we decided to supplement the protocol-specific informed consent form with the following: (1) a short pamphlet for the prospective participant that includes a series of questions that she or he is encouraged to ask the investigator, and (2) a more detailed companion guide for investigators to help them develop simple-language answers to the questions. Both documents are available to use or modify.</p> <p>CONCLUSIONS: We propose an approach to obtaining informed consent for NGS studies that encourages discussion of key issues without creating a complex, comprehensive document for participants; it also maximizes investigator flexibility. We also suggest mechanisms to return restricted information to participants.</p>
dc.identifier.submissionpathumccts_pubs/222
dc.contributor.departmentUMass Center for Clinical and Translational Science
dc.source.pages115-120


This item appears in the following Collection(s)

Show simple item record